Evidence map›Paper›PMID 31677085›Full record

ArticleInfection2020

Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections.

Yishu Tang, Xinyu Wu, Qian Cheng, Xin Li

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Antibiotic therapy in febrile neutropenia in haematological patients: current considerations and future challenges.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yishu TangDepartment of Emergency, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xinyu WuDepartment of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Qian ChengDepartment of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xin LiDepartment of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. lixiner1975@163.com.
Central South University · CNThird Xiangya Hospital · CN

Funding

Fundamental Research Funds for the Central Universities of Central South University No.2017zzts837National Natural Science Foundation of China (NSFC) 81870165
6 · The paper itself

Abstract

backgroundInappropriate initial antimicrobial therapy (IIAT) may increase the mortality rate of hematological malignancies (HMs) patients with Gram-negative bacteria bloodstream infections (GN-BSI). The aim of this study is to determine whether IIAT affects the prognosis in this patient population and recommend the appropriate antibiotic regimen to minimize IIAT.

methodsWe reviewed a retrospective cohort study of 361 HM patients with neutropenic fever from GN-BSI. The patients' clinical characteristics and the results of the drug sensitivity test in vitro were analyzed.

resultsIIAT rate was 21.3% in HM patients with neutropenic fever caused by GN-BSI. There was a significant difference in 7-day mortality rate between patients treated with appropriate antibiotics and those with IIAT (7.7% vs 29.9%, p < 0.01). Multivariate analysis confirmed that IIAT was an independent risk factors for early mortality [4.860 (1.541-15.323)]. Drug sensitivity data of GN-bacteria suggested that carbapenems monotherapy or beta-lactamase inhibitors (BLBLI) combined with amikacin as the initial therapy can effectively reduce the IIAT rate. In the stratified antibiogram based on prior antimicrobial exposure, our results showed that BLBLI monotherapy could be initially used as an empirical treatment in patients without prior antimicrobial exposure. In those who had received prior antimicrobial exposure, BLBLI (especially piperacillin-tazobactam) combined with amikacin is recommended.

conclusionsIIAT was a critical factor contributing to the mortality of HM patients with neutropenic fever from GN-BSI.

Indexed as

AdolescentAdultAgedAged, 80 and overAnti-Infective AgentsChinaFemaleGram-Negative Bacterial InfectionsHematologic NeoplasmsHumansInappropriate PrescribingMaleMiddle AgedYoung AdultAnti-Infective AgentsFebrile neutropeniaGram-negative bloodstream infectionsHematological malignanciesInappropriate initial antimicrobial therapy

Identifiers

PMID31677085
OpenAlexW2987460502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.